LIQUID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION OF A CGRP ANTAGONIST

Liquid formulations comprising the compound 1-[1-({[(3R,6S)-6-(2,3-difluo rophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]amino}carbonyl)piperidin -4-yl]-2-oxo-1,2-dihydroimidazo[4,5-b]pyridin-3-ide have surprisingly improv ed bioavailability and stability in comprising polyethylene glycol, Twee...

Full description

Saved in:
Bibliographic Details
Main Authors THOMPSON, KAREN, BRESLIN, DAVID, STELLABOTT, JOYCE, ALANI, LAMAN L, JAHANSOUZ, HOSSAIN
Format Patent
LanguageEnglish
French
Published 13.03.2008
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
TRAPPING
Online AccessGet full text

Cover

More Information
Summary:Liquid formulations comprising the compound 1-[1-({[(3R,6S)-6-(2,3-difluo rophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]amino}carbonyl)piperidin -4-yl]-2-oxo-1,2-dihydroimidazo[4,5-b]pyridin-3-ide have surprisingly improv ed bioavailability and stability in comprising polyethylene glycol, Tween (p olysorbate 80), Cremophor® EL (polyoxyl 35 castor oil), propylene glycol, an d optionally water, and may be filled into soft or hard gelatin capsules use ful for treating conditions including migraine headache and cluster headache .
Bibliography:Application Number: CA20072662748